DUPIXENT IMPROVED COPD
PATIENTS’ DAILY QUALITY OF LIFE1,2
Improvement as measured by SGRQ5
of patients reported a clinically
meaningful (≥4-point)
improvement at
Week 52
with DUPIXENT vs
43% for placebo
(N=939; OR: 1.44; 95% CI: 1.10,
1.89; P=0.009)1,2
51% responder rate at Week 52
for subjects treated with
DUPIXENT vs 47% for
placebo
(N=721;
OR: 1.16; 95% CI: 0.86,
1.58)1,3
NOTUS results are descriptive. Definitive conclusions cannot be made.
The sgrq measures the
qualitative impact of
copd2,5
SGRQ is a disease-specific
instrument designed to measure
impact on overall
health, daily life,
and
perceived well-being in
patients with COPD
Symptoms
Cough, sputum
production,
breathlessness,
and
wheezing
Activity
Disruption of daily
physical activity
Impacts
Disturbance to
psychosocial function
In NOTUS, patients receiving DUPIXENT + SOC (n=362) experienced -9.8
reduction in total SGRQ score vs
-6.4 with placebo + SOC (n=359) (LSM
difference: -3.4 [95% CI: -5.8,
-0.9]).4
NOTUS results are descriptive. Definitive conclusions cannot be made.
Standard of care was triple inhaled therapy (LAMA+LABA+ICS).1,4
DUPIXENT REDUCED
SGRQ SCORES–LOWER SGRQ
SCORES INDICATE IMPROVED
QUALITY OF
LIFE1,3
Standard of care was triple inhaled
therapy
(LAMA+LABA+ICS).1,4
ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LSM, least squares mean; OR, odds ratio; SGRQ, St George's Respiratory Questionnaire; SOC, standard of care.